About Aptuit
Aptuit is a company based in Greenwich (United States) founded in 2004 was acquired by Evotec in July 2017. Aptuit has raised $14.23 million across 4 funding rounds from investors including Evotec, Welsh, Carson, Anderson & Stowe and Temasek. Aptuit has completed 2 acquisitions, including Exquiron and Kuecept. Aptuit offers products and services including Pipeline Co-Creation, CRO Services, CDMO Services, and PanOmics Platform. Aptuit operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Greenwich, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.23 M (USD)
in 4 rounds
-
Latest Funding Round
$271.63 K (USD), Grant
Jan 01, 2017
-
Investors
Evotec
& 3 more
-
Employee Count
Not available
-
Investments & Acquisitions
Exquiron
& 1 more
-
Acquired by
Evotec
(Jul 30, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aptuit
Aptuit offers a comprehensive portfolio of products and services, including Pipeline Co-Creation, CRO Services, CDMO Services, and PanOmics Platform.
Service for co-creating drug pipelines with partners
Outsourced R&D for therapeutic development and testing
Contract development and manufacturing of biotherapeutics
AI-driven tool for disease understanding and drug discovery
Funding Insights of Aptuit
Aptuit has successfully raised a total of $14.23M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $271.63 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aptuit
Aptuit has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Evotec, Welsh, Carson, Anderson & Stowe and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
Healthcare and technology sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Aptuit
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aptuit
Aptuit has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Exquiron and Kuecept.
Investment portfolio details for Aptuit
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Early-stage drug discovery services are provided as a CRO.
|
Locked | Locked | 2012 | Locked | |
|
Preclinical formulation, chemistry, manufacturing, and control services are provided.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Aptuit
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aptuit
Detailed financials for Aptuit
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aptuit Comparisons
Peer comparison for Aptuit
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aptuit
Aptuit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of Aptuit
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aptuit
Complete news archive for Aptuit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aptuit
Aptuit was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Aptuit is headquartered in Greenwich, United States. It is registered at Greenwich, Connecticut, United States.
Aptuit is a funded company, having raised a total of $14.23M across 4 funding rounds to date.
Aptuit was founded in 2004 in Greenwich, United States, within the pharmaceutical sector. Contract research and development services for small molecules are provided, encompassing drug discovery, preclinical testing, API development and manufacturing, and finished product formulations for inhalation, solid, and oral dosages. A custom Indigo service is also offered to enhance drug bioavailability. Operations focus on supporting pharmaceutical innovation through these specialized capabilities.
Aptuit's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Aptuit offers Pipeline Co-Creation, CRO Services, CDMO Services, and PanOmics Platform.
Aptuit has 4 investors. Key investors include Evotec, Welsh, Carson, Anderson & Stowe, Temasek, and European Union.